{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:58:03Z","timestamp":1773939483495,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10637-023-01347-6","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T10:06:22Z","timestamp":1680084382000},"page":"333-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis"],"prefix":"10.1007","volume":"41","author":[{"given":"Chunjiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanqing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"1347_CR1","doi-asserted-by":"publisher","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al Management of Immune-Related adverse events in patients treated with Immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2018 Jun10;36(17):1714\u20131768. doi: https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","DOI":"10.1200\/JCO.2017.77.6385"},{"issue":"9","key":"1347_CR2","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1080\/21645515.2016.1175694","volume":"12","author":"A Rajan","year":"2016","unstructured":"Rajan A, Kim C, Heery CR, Guha U, Gulley JL (2016) Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancers. Hum Vaccin Immunother 12(9):2219\u20132231. https:\/\/doi.org\/10.1080\/21645515.2016.1175694","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"1347_CR3","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26(12):2375\u20132391. https:\/\/doi.org\/10.1093\/annonc\/mdv383","journal-title":"Ann Oncol"},{"key":"1347_CR4","doi-asserted-by":"publisher","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al (2000 Jul) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 70(1):327\u2013334. https:\/\/doi.org\/10.1016\/s0003-4975(00)01595-2","DOI":"10.1016\/s0003-4975(00)01595-2"},{"issue":"10","key":"1347_CR5","doi-asserted-by":"publisher","first-page":"e1426","DOI":"10.1212\/WNL.0000000000010209","volume":"95","author":"M Tomschik","year":"2020","unstructured":"Tomschik M, Hilger E, Rath J, Mayer EM, Fahrner M, Cetin H et al (2020) Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. Neurology 95(10):e1426\u2013e1436. https:\/\/doi.org\/10.1212\/WNL.0000000000010209","journal-title":"Neurology"},{"issue":"26","key":"1347_CR6","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Myasthenia Gravis (2016) N Engl J Med 375(26):2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"issue":"10","key":"1347_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","volume":"18","author":"JC Kao","year":"2018","unstructured":"Kao JC, Brickshawana A, Liewluck T (2018) Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep 18(10):63. https:\/\/doi.org\/10.1007\/s11910-018-0878-7","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"11","key":"1347_CR8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127\u20131134. https:\/\/doi.org\/10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"issue":"7","key":"1347_CR9","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1016\/j.jtho.2017.02.024","volume":"12","author":"RYC Tan","year":"2017","unstructured":"Tan RYC, Toh CK, Takano A (2017) Continued response to one dose of Nivolumab complicated by Myasthenic Crisis and Myositis. J Thorac Oncol 12(7):e90\u2013e91. https:\/\/doi.org\/10.1016\/j.jtho.2017.02.024","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1347_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/trstmh\/tru167","volume":"109","author":"SL Klein","year":"2015","unstructured":"Klein SL, Marriott I, Fish EN (2015) Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg 109(1):9\u201315. https:\/\/doi.org\/10.1093\/trstmh\/tru167","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"1347_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.it.2013.10.006","volume":"35","author":"JG MMarkle","year":"2014","unstructured":"MMarkle JG, Fish EN (2014) SeXX matters in immunity. Trends Immunol 35(3):97\u2013104. https:\/\/doi.org\/10.1016\/j.it.2013.10.006","journal-title":"Trends Immunol"},{"key":"1347_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fneur.2018.00150","volume":"9","author":"V Montes","year":"2018","unstructured":"Montes V, Sousa S, Pita F, Guerreiro R, Carmona C (2018) Myasthenia Gravis Induced by Ipilimumab in a patient with metastatic melanoma. Front Neurol 9:150. https:\/\/doi.org\/10.3389\/fneur.2018.00150","journal-title":"Front Neurol"},{"issue":"33","key":"1347_CR13","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","volume":"33","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR et al (2015) Myasthenia Gravis Induced by Ipilimumab in patients with metastatic melanoma. J Clin Oncol 33(33):e122\u2013e124. https:\/\/doi.org\/10.1200\/JCO.2013.51.1683","journal-title":"J Clin Oncol"},{"issue":"4","key":"1347_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16(4):589\u2013593. https:\/\/doi.org\/10.1093\/neuonc\/nou001","journal-title":"Neuro Oncol"},{"issue":"2","key":"1347_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/01.md.0000209337.59874.aa","volume":"85","author":"V Purvin","year":"2006","unstructured":"Purvin V, Kawasaki A, Smith KH, Kesler A (2006) Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Med (Baltim) 85(2):82\u201385. https:\/\/doi.org\/10.1097\/01.md.0000209337.59874.aa","journal-title":"Med (Baltim)"},{"issue":"1","key":"1347_CR16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000498985","volume":"12","author":"N Agrawal","year":"2019","unstructured":"Agrawal N, Khunger A, Vachhani P, Colvin TA, Hattoum A, Spangenthal E et al (2019) Cardiac Toxicity Associated with Immune Checkpoint inhibitors: Case Series and Review of the literature. Case Rep Oncol 12(1):260\u2013276. https:\/\/doi.org\/10.1159\/000498985","journal-title":"Case Rep Oncol"},{"issue":"1","key":"1347_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME et al (2019) Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7(1):319. https:\/\/doi.org\/10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"1347_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE et al (2019) Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Cancer Netw 17:255\u2013289. https:\/\/doi.org\/10.6004\/jnccn.2019.0013","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10","key":"1347_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.14740\/jmc3783","volume":"12","author":"N Tahir","year":"2021","unstructured":"Tahir N, Mahboob A, Piao X, Ying G, Shrestha J, Sherchan R, Zahra F (2021) Nivolumab, a double-edged Sword: a Case Report of Nivolumab-Induced Myasthenia Gravis. J Med Cases 12(10):424\u2013428. https:\/\/doi.org\/10.14740\/jmc3783","journal-title":"J Med Cases"},{"issue":"2","key":"1347_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.33588\/rn.7002.2019153","volume":"70","author":"B Mi\u00f1\u00f3n-Fern\u00e1ndez","year":"2020","unstructured":"Mi\u00f1\u00f3n-Fern\u00e1ndez B, Losada-Domingo JM, S\u00e1nchez-Horvath MT, B\u00e1rcena-Llona J (2020) Myasthenia gravis associated with nivolumab. Rev Neurol 70(2):72\u201373 Spanish. https:\/\/doi.org\/10.33588\/rn.7002.2019153","journal-title":"Rev Neurol"},{"issue":"6","key":"1347_CR21","doi-asserted-by":"publisher","first-page":"e229149","DOI":"10.1136\/bcr-2018-229149","volume":"12","author":"A Dhenin","year":"2019","unstructured":"Dhenin A, Samartzi V, Lejeune S, Seront E (2019) Cascade of immunologic adverse events related to pembrolizumab treatment. BMJ Case Rep 12(6):e229149. https:\/\/doi.org\/10.1136\/bcr-2018-229149","journal-title":"BMJ Case Rep"},{"issue":"5","key":"1347_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1212\/wnl.36.5.729","volume":"36","author":"RG Miller","year":"1986","unstructured":"Miller RG, Milner-Brown HS, Mirka A (1986) Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology 36(5):729\u2013732. https:\/\/doi.org\/10.1212\/wnl.36.5.729","journal-title":"Neurology"},{"issue":"3","key":"1347_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A et al (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 update. Neurology 96(3):114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"issue":"8","key":"1347_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/CJI.0000000000000278","volume":"42","author":"O Becquart","year":"2019","unstructured":"Becquart O, Lacotte J, Malissart P, Nadal J, Lesage C, Guillot B, Du Thanh A (2019) Myasthenia Gravis Induced by Immune Checkpoint inhibitors. J Immunother 42(8):309\u2013312. https:\/\/doi.org\/10.1097\/CJI.0000000000000278","journal-title":"J Immunother"},{"issue":"3","key":"1347_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/cancers11030296","volume":"11","author":"A Mirabile","year":"2019","unstructured":"Mirabile A, Brioschi E, Ducceschi M, Piva S, Lazzari C, Bulotta A et al (2019) PD-1 inhibitors-related neurological toxicities in patients with non-small-cell Lung Cancer: A literature review. Cancers (Basel) 11(3):296. https:\/\/doi.org\/10.3390\/cancers11030296","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1347_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.18999\/NAGJMS.78.1.119","volume":"78","author":"O Maeda","year":"2016","unstructured":"Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M, Ando Y (2016) Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci 78(1):119\u2013122. https:\/\/doi.org\/10.18999\/NAGJMS.78.1.119","journal-title":"Nagoya J Med Sci"},{"key":"1347_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3389\/fonc.2019.00084","volume":"9","author":"JM Werner","year":"2019","unstructured":"Werner JM, Schweinsberg V, Schroeter M, von Reutern B, Malter MP, Schlaak M et al (2019) Successful treatment of Myasthenia Gravis following PD-1\/CTLA-4 combination checkpoint blockade in a patient with metastatic melanoma. Front Oncol 9:84. https:\/\/doi.org\/10.3389\/fonc.2019.00084","journal-title":"Front Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01347-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T08:09:30Z","timestamp":1682582970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01347-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1347"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01347-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}